Objective : To propose and model a 2-tier intervention: 1. 2g/day sodium restriction to reduce metabolic inflammation. 2. Bupropion/Naltrexone to stimulate POMC neurons and block opioid-mediated autoinhibition.

Methods: Narrative synthesis of preclinical and clinical data on sodium, inflammation, and MC4R pharmacology.

Results: The combined approach targets both the inflammatory environment and the downstream satiety circuit.

Conclusion: Bypassing leptin resistance via dual lifestyle + pharmacological targeting may improve appetite control in leptin-resistant adults.

1. Introduction

   
   

Hyperphagia in adults with obesity often persists despite high circulating leptin, indicating leptin resistance. Contributing factors include hypothalamic gliosis, systemic inflammation, and impaired melanocortin signaling. 

Current GLP-1 based therapies suppress appetite but do not directly correct leptin/MC4R pathway dysfunction and show high weight regain after cessation.

We hypothesize that combining anti-inflammatory dietary sodium restriction with direct MC4R pathway activation will improve outcomes.

2. Methods

2.1 Study Design

This is a theoretical framework + literature synthesis. A future RCT would randomize adults with BMI ≥30 and hyperphagia scores ≥20 into 4 arms for 24 weeks:

1. Control: Standard dietary counseling

2. Na-2g: 2g sodium/day diet + counseling

3. BN: Bupropion 360mg SR + Naltrexone 32mg SR daily + standard diet

4. Combo :  Na-2g + BN + counseling

2.2 Participants

Inclusion: Age 18-65, BMI 30-45, stable weight ±3kg for 3 months, elevated CRP >2mg

Exclusion: Uncontrolled HTN, seizure disorder, chronic opioid use, renal disease.

2.3 Interventions

Tier 1 - Sodium: All food provided to achieve 2000mg Na/day. Monitored by 24h urine sodium.

Tier 2 - Pharmacology: Bupropion/Naltrexone titrated over 4 weeks to 360/32mg. Based on mechanism of POMC stimulation + opioid antagonism.

2.4 Outcomes

Primary : Change in hyperphagia score and body weight at 24 weeks.

Secondary : CRP, IL-6, 24h urine Na, leptin, body composition via DEXA, food reward questionnaires.

Mechanistic : fMRI food cue reactivity.

2.5 Statistical Analysis

ANCOVA adjusted for baseline BMI, sex, age. Power 80% to detect 5% weight difference.

3. Results - Projected from Literature

3.1 Inflammation and Sodium

High Na diets increase IL-6, TNF-α, and hypothalamic inflammation. A 2g/day limit is projected to reduce CRP by 15-20% independent of weight loss, based on DASH-sodium trials.

3.2 Pharmacology

Bupropion stimulates POMC neurons to release α-MSH → MC4R activation → satiety.

Naltrexone blocks β-endorphin mediated autoinhibition of POMC neurons, preventing signal shutdown.

In trials, BN combo produced ∼6-8% weight loss at 56 weeks vs 1-2% placebo.

3.3 Combined Effect - Projected

Weight: Combo arm -12% vs BN -7% vs Na-2g -4% vs Control -2% at 24w.

Body Composition: Na-2g expected to preserve more FFM vs BN alone, consistent with intensive lifestyle retaining more lean mass than GLP-1RA.

Hyperphagia: Combo expected to show largest reduction in hunger and food cravings due to dual mechanism.

Inflammation: Only Combo and Na-2g arms show significant CRP reduction.

4. Discussion

This model addresses 2 failures in obesity treatment:

1. The environment : High sodium maintains inflammatory tone that worsens leptin resistance.

2. The circuit : Leptin resistance blocks natural satiety. BN bypasses this by acting downstream at POMC.

Compared to GLP-1RA, which reduce energy intake by 35% via delayed gastric emptying and reward changes, BN directly targets homeostatic hunger. GLP-1RA also show greater FFM loss, whereas Tier 1 sodium + lifestyle may protect lean mass.

Limitations: 

Adherence to 2g Na is difficult. 

BN has CV and neuropsychiatric side effects. 

Long term weight maintenance post-BN is unknown.

5. Conclusion

A multi-tiered approach combining 2g sodium restriction to reduce metabolic inflammation with Bupropion/Naltrexone to activate POMC-MC4R signaling provides a mechanistically rational strategy for leptin-resistant hyperphagia. Clinical testing is warranted.

6. References

1. Mechanism of sodium-induced inflammation and hypothalamic resistance.

2. Bupropion/Naltrexone and POMC neuron activation.

3. GLP-1RA effects on energy intake and gastric emptying.

4. Intensive lifestyle vs GLP-1RA: lean mass retention.

5. Multi-receptor agonism for obesity and metabolic disease.

6. Opioid modulation of melanocortin pathways.